CompletedNot Applicable

Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization

China113,035 participantsStarted 2022-11-30

Plain-language summary

The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of symptom onset in different age groups (18 to 80 years and above 80 years).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient registered in the Chinese Stroke Centre Alliance (CSCA) platform from Aug 2015 to Jul 2019 * ≥18 years old * Diagnosed as Acute Ischemic Stroke (AIS) at admission * Arrived or admitted into hospital within 4.5 hours of symptom onset * For patients in the iv rt-PA groups only: received IV rt-PA within 4.5 hours of symptom onset Exclusion Criteria: * Documented Intravenous Thrombolysis (IVT) absolute contraindication * Key data missing (age, gender, baseline National Institutes of Health Stroke Scale \[NIHSS\], time of symptom onset, IVT treated or not, time of IV alteplase treatment) * Received thrombolysis agents other than IV rt-PA (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase) * Received endovascular treatment * Received IV rt-PA after 4.5 hours of symptom onset

What they're measuring

All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients

Timeframe: Up to 100 days.

Trial details

NCT IDNCT05395351

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-03-28

Results submitted2024-03-21

View on ClinicalTrials.gov More Stroke trials